Hypertension in adult polycystic kidney disease: a narrative review

被引：0
作者：
Mian, Sarah [1 ]
Acharya, Yogesh [1 ]
Dahal, Ranjan [2 ]
机构：
[1] Avalon Univ, Sch Med, Curacao, Neth Antilles
[2] St Peters Univ Hosp, New Brunswick, NJ 08901 USA
来源：
JOURNAL OF RENAL INJURY PREVENTION | 2019年 / 8卷 / 02期
关键词：
Adult polycystic kidney disease; Hypertension; Antihypertensive agents; Prevention and control; Renin-angiotensin-aldosterone system; End stage renal disease; Glomerular filtration rate; Chronic kidney disease; CONVERTING-ENZYME-INHIBITORS; BLOOD-PRESSURE; ENDOTHELIN; PROGRESSION; ADPKD;
D O I：
10.15171/jrip.2019.23
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited renal disorder that impacts approximately 12 million worldwide. It is characterized by bilateral kidney enlargement and cystic growth. Hypertension (HTN) is a focal point in the management of ADPKD and is linked to a faster progression to end stage renal disease. Current novel therapies have proven to reduce the progression of renal damage. The ideal goal is to minimize risk through preventative studies and pharmacology to further increase life expectancy and quality. The purpose of this article is to highlight the importance of blood pressure management in ADPKD and review current literature to determine the most effective preventative pharmacotherapy.
引用
收藏
页码：122 / 126
页数：5
相关论文
共 39 条
[1]  
Akoh Jacob A, 2015, World J Nephrol, V4, P468, DOI 10.5527/wjn.v4.i4.468
[2]   Autosomal dominant polycystic kidney disease (ADPKD, MIM 173900, PKD1 and PKD2 genes, protein products known as polycystin-1 and polycystin-2) [J].
Boucher, C ;
Sandford, R .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2004, 12 (05) :347-354
[3]   THE RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM AND AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY-DISEASE [J].
CHAPMAN, AB ;
JOHNSON, A ;
GABOW, PA ;
SCHRIER, RW .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (16) :1091-1096
[4]   Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference [J].
Chapman, Arlene B. ;
Devuyst, Olivier ;
Eckardt, Kai-Uwe ;
Gansevoort, Ron T. ;
Harris, Tess ;
Horie, Shigeo ;
Kasiske, Bertram L. ;
Odland, Dwight ;
Pei, York ;
Perrone, Ronald D. ;
Pirson, Yves ;
Schrier, Robert W. ;
Torra, Roser ;
Torres, Vicente E. ;
Watnick, Terry ;
Wheeler, David C. .
KIDNEY INTERNATIONAL, 2015, 88 (01) :17-27
[5]   Hypertension in Autosomal Dominant Polycystic Kidney Disease [J].
Chapman, Arlene B. ;
Stepniakowski, Konrad ;
Rahbari-Oskoui, Frederic .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2010, 17 (02) :153-163
[6]   The HALT Polycystic Kidney Disease Trials: Design and Implementation [J].
Chapman, Arlene B. ;
Torres, Vicente E. ;
Perrone, Ronald D. ;
Steinman, Theodore I. ;
Bae, Kyongtae T. ;
Miller, J. Philip ;
Miskulin, Dana C. ;
Oskoui, Frederic Rahbari ;
Masoumi, Arnirali ;
Hogan, Marie C. ;
Winklhofer, Franz T. ;
Braun, William ;
Thompson, Paul A. ;
Meyers, Catherine M. ;
Kelleher, Cass ;
Schrier, Robert W. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 5 (01) :102-109
[7]  
de Almeida Edgar A F, 2007, Rev Port Cardiol, V26, P235
[8]   Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease [J].
Ecder, T ;
Edelstein, CL ;
Fick-Brosnahan, GM ;
Johnson, AM ;
Chapman, AB ;
Gabow, PA ;
Schrier, RW .
AMERICAN JOURNAL OF NEPHROLOGY, 2001, 21 (02) :98-103
[9]  
Ecder T, 2001, J AM SOC NEPHROL, V12, P194, DOI 10.1681/ASN.V121194
[10]   Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease [J].
Ecder, T ;
Chapman, AB ;
Brosnahan, GM ;
Edelstein, CL ;
Johnson, AM ;
Schrier, RW .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (03) :427-432
1234